’ Regd. Office: Dr Lat PariLabs bid, Mock, Sector if, Robinl, New Dete1 10005
F ‘Webs wiv. typathiabs com, CIN: L7P908 1995710065 tea
Tm
= | DR SAMEER GUPTA hr I
Collected: NNN 4:50:00AM : 17/4/2025 6:56:41AM
Alc Status :P ‘atus ; Final |
Collected at: ASHIRVAD MULTI SPECIALITY HOSPITAL Processed at; Or, Lal Path Labs Ltd |
Mahmoor Gan}, Ashirvad Hospital, Varanas! - Mahmoorganj ,Varanasi - 221010 |
2210010
Test Report

Dc P| L P|

| BILIRUBIN TOTAL, DIRECT AND INDIRECT, SERUM
| (Diazo)

| Bilirubin Total 10.95 mg/dL 1,50 - 12.00

” | Bilirubin Direct 0.35 mg/dL 0.00 - 0.40

| Bilirubin Indirect 10.60 mg/dL <1.10

Comment

Unconjugated hyperbilirubinemia poses a risk for development of Kernicterus, especially in low birth weight

infants. Most neonates develop mild unconjugated hyperbilirubinemia between days 2and Safter birth. Peak

levels are typically 5-10 mg/dL and decline to normal level within 2 weeks. It is recommended to interpret

bilirubin levels according to infant's ay Hil EE SS ES ES

concentration above 10 mg/dL coupled with prematurity, low serum albumin, acidosis, and substances that
complete with binding site albumin (eg. ceftriaxone, sulfisoxarole, aspirin), may increase the risk for
Kemicterus.
ee NS La Na he ae
| C-REACTIVE PROTEIN; CRP, SERUM 6.50 mg/L <6.00
(Immunoturbidimetry)

A = J